These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 38899589)
1. Drug disposition in cholestasis: An important concern. Shang T; Zhang C; Liu D Pharmacol Res Perspect; 2024 Aug; 12(4):e1220. PubMed ID: 38899589 [TBL] [Abstract][Full Text] [Related]
2. Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs. Notenboom S; Weigand KM; Proost JH; van Lipzig MMH; van de Steeg E; van den Broek PHH; Greupink R; Russel FGM; Groothuis GMM Eur J Pharm Sci; 2018 Mar; 115():175-184. PubMed ID: 29309877 [TBL] [Abstract][Full Text] [Related]
3. Effects of Yinzhihuang on Alleviating Cyclosporine A-Induced Cholestatic Liver Injury via Farnesoid X Receptor-Mediated Regulation of Transporters and Enzymes in Vitro and in Vivo. Qin Y; Tan J; Han X; Wang N; Zhai X; Lu Y Biol Pharm Bull; 2023; 46(12):1810-1819. PubMed ID: 38044100 [TBL] [Abstract][Full Text] [Related]
4. An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. Yang K; Köck K; Sedykh A; Tropsha A; Brouwer KL J Pharm Sci; 2013 Sep; 102(9):3037-57. PubMed ID: 23653385 [TBL] [Abstract][Full Text] [Related]
5. Geniposide attenuates ANIT-induced cholestasis through regulation of transporters and enzymes involved in bile acids homeostasis in rats. Wang L; Wu G; Wu F; Jiang N; Lin Y J Ethnopharmacol; 2017 Jan; 196():178-185. PubMed ID: 27988401 [TBL] [Abstract][Full Text] [Related]
6. Drug disposition alterations in liver disease: extrahepatic effects in cholestasis and nonalcoholic steatohepatitis. Canet MJ; Cherrington NJ Expert Opin Drug Metab Toxicol; 2014 Sep; 10(9):1209-19. PubMed ID: 24989624 [TBL] [Abstract][Full Text] [Related]
7. Pharmacology. A worrisome side effect of an antianxiety remedy. Vogel G Science; 2001 Jan; 291(5501):37. PubMed ID: 11192003 [No Abstract] [Full Text] [Related]
8. Altered expression of nuclear receptors affects the expression of metabolic enzymes and transporters in a rat model of cholestasis. Hasegawa Y; Kishimoto S; Takahashi H; Inotsume N; Takeuchi Y; Fukushima S Biol Pharm Bull; 2009 Dec; 32(12):2046-52. PubMed ID: 19952426 [TBL] [Abstract][Full Text] [Related]
9. Cholestasis: the ABCs of cellular mechanisms for impaired bile secretion--transporters and genes. Shaffer EA Can J Gastroenterol; 2002 Jun; 16(6):380-9. PubMed ID: 12096302 [TBL] [Abstract][Full Text] [Related]
10. Organic solute transporter OSTα/β is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury. Malinen MM; Ali I; Bezençon J; Beaudoin JJ; Brouwer KLR Am J Physiol Gastrointest Liver Physiol; 2018 May; 314(5):G597-G609. PubMed ID: 29420067 [TBL] [Abstract][Full Text] [Related]
11. Model Systems for Studying the Role of Canalicular Efflux Transporters in Drug-Induced Cholestatic Liver Disease. Stieger B; Mahdi ZM J Pharm Sci; 2017 Sep; 106(9):2295-2301. PubMed ID: 28385542 [TBL] [Abstract][Full Text] [Related]
12. Reversible bile acid changes in bile duct obstruction and its potential for hepatocellular injury. Vitale GC; Siow Y; Baker PR; Cuschieri A J Hepatol; 1992 Mar; 14(2-3):151-6. PubMed ID: 1500678 [TBL] [Abstract][Full Text] [Related]
13. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis. Meng Q; Chen XL; Wang CY; Liu Q; Sun HJ; Sun PY; Huo XK; Liu ZH; Yao JH; Liu KX Toxicol Appl Pharmacol; 2015 Mar; 283(3):178-86. PubMed ID: 25655198 [TBL] [Abstract][Full Text] [Related]
14. Bile acid metabolism and FXR-mediated effects in human cholestatic liver disorders. Molinaro A; Marschall HU Biochem Soc Trans; 2022 Feb; 50(1):361-373. PubMed ID: 35191955 [TBL] [Abstract][Full Text] [Related]
15. Bile acid homeostasis paradigm and its connotation with cholestatic liver diseases. Yang T; Khan GJ; Wu Z; Wang X; Zhang L; Jiang Z Drug Discov Today; 2019 Jan; 24(1):112-128. PubMed ID: 30244079 [TBL] [Abstract][Full Text] [Related]
16. Pravastatin modulates liver bile acid and cholesterol homeostasis in rats with chronic cholestasis. Kolouchova G; Brcakova E; Hirsova P; Sispera L; Tomsik P; Cermanova J; Hyspler R; Slanarova M; Fuksa L; Lotkova H; Micuda S J Gastroenterol Hepatol; 2011 Oct; 26(10):1544-51. PubMed ID: 21501227 [TBL] [Abstract][Full Text] [Related]
17. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Isoherranen N; Thummel KE Drug Metab Dispos; 2013 Feb; 41(2):256-62. PubMed ID: 23328895 [TBL] [Abstract][Full Text] [Related]
18. Molecular regulation of sinusoidal liver bile acid transporters during cholestasis. Gartung C; Matern S Yale J Biol Med; 1997; 70(4):355-63. PubMed ID: 9626756 [TBL] [Abstract][Full Text] [Related]
19. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Köck K; Ferslew BC; Netterberg I; Yang K; Urban TJ; Swaan PW; Stewart PW; Brouwer KL Drug Metab Dispos; 2014 Apr; 42(4):665-74. PubMed ID: 24154606 [TBL] [Abstract][Full Text] [Related]
20. Danning tablets attenuates α-naphthylisothiocyanate-induced cholestasis by modulating the expression of transporters and metabolic enzymes. Ding L; Zhang B; Zhan C; Yang L; Wang Z BMC Complement Altern Med; 2014 Jul; 14():249. PubMed ID: 25033983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]